A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

NCT03733301 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

329

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Baricitinib
DRUG: Topical corticosteroid
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]